Clinical-stage biopharmaceutical company 89bio ( NASDAQ: ETNB ) priced its previously announced upsized underwritten public offering of 11.46M shares at a price per share of $8.50 and pre-funded warrants to purchase up to 3.
25M shares at a public offering price of $8.499. Underwriters have.
